Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

Share this content:
Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer
Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer, a study published in the journal Cancer has shown.1

For the study, investigators enrolled 62 patients with measurable triple-negative locally advanced or metastatic breast cancer who had received no prior chemotherapy for their disease. Of those, 74% had received adjuvant chemotherapy and 65% had visceral metastases.

Participants received paclitaxel 80 mg/m2 intravenously on days 1, 8, and 15, capecitabine 800 mg/m2 orally twice daily on days 1 to 5, 8 to 12, and 15 to 19, and bevacizumab 10 mg/kg on days 1 and 14. Paclitaxel was administered for up to 6, 4-week cycles, while capecitabine and bevacizumab were administered until disease progression or unacceptable toxicity.

Results showed that the objective response rate was 77% (95% CI, 66-88), which included complete responses in 19% of patients. The median duration of response was 5.6 months.

Researchers found that median progression-free survival and overall survival were 7.6 months (95% CI, 6.3-9.0) and 19.2 months (95% CI, 17.4-20.9), respectively.

In terms of safety, the most common grade 3 or higher adverse events were hypertension (35%) and neutropenia (23%); 5% of patients experienced febrile neutropenia.

In addition, investigators observed grade 2 or higher hand-foot syndrome, alopecia, and nail toxicity each in 40% of patients.

Of note, 22% of patients required treatment interruption due to toxicity.


1. Ferrero JM, Hardy-Bessard AC, Capitain O, et al. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Cancer. 2016 Jul 14. doi:10.1002/cncr.30170. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs